Document is current
Any future updates will be listed below
-
Authors
Golmohammadi, Mobina https://orcid.org/0000-0003-0492-0923
Raza, Shahzad https://orcid.org/0000-0002-2739-2265
Albayyadhi, Maram
Sholehrasa, Hossein
Khouri, Jack https://orcid.org/0000-0002-2473-6528
Williams, Louis
Hansen, Doris K. https://orcid.org/0000-0002-9813-3578
Moradi, Azam
Xu, Xuan
Albliwi, Moath
Ali, Ali Hajj
Dima, Danai https://orcid.org/0000-0002-3587-7975
Anwer, Faiz https://orcid.org/0000-0001-6914-7439
Paul, Barry
Jaberi-Douraki, Majid https://orcid.org/0000-0002-8505-6550
-
Funding
Funding for this research was provided by:
BioNexus KC 20-7 Nexus of Animal and Human Health Research Grant
- License Information
-
More Information
Article History
Received: 4 February 2025
Revised: 19 June 2025
Accepted: 9 July 2025
First Online: 1 August 2025
Competing interests
: SR received an honorarium as an advisory board for Pfizer, Prothena Biosciences, KiTE pharma Nexcella and Janssen and received research funding (outside of this study) from Nexcella Inc, Poseida Therapeutics and Janssen. JK: Consultancy and honoraria: Janssen, GPCR therapeutics, and Prothena. LW is a local principal investigator for Pfizer and Abbvie clinical trials and received honorarium for advisory board meeting for Janssen/J&J Consulting. DH is supported by the NCI (R01CA281756-01A1) and the Pentecost Family Myeloma Research Center and reports research funding from Bristol-Myers Squibb, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting or advisory role for Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma, AstraZeneca, and Karyopharm. FA served as the local principal investigator for Allogene Therapeutics, Bristol Myers Squibb, Celgene, and GlaxoSmithKline and served as the advisor and speaker for Bristol Myers Squibb/Celgene. Other authors declare non-relevant declare non-financial interests.
